A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

NCT02604212 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision to discontinue trial

Conditions

Hepatitis B

Interventions

DRUG: ARC-520
OTHER: Placebo
DRUG: entecavir
DRUG: antihistamine
DRUG: tenofovir

Sponsor

Arrowhead Pharmaceuticals